India's biopharmaceutical major Biocon Limited said its subsidiary Biocon Biologics Limited has received approval from the Drugs Controller General of India (DCGI) for its extracorporeal blood purification (EBP) device, CytoSorb, which could help reduce pro-inflammatory cytokines levels in critical COVID-19 patients.
According to a Biocon media release, the license will be effective until the COVID-19 outbreak is controlled in the country and will be used as an emergency therapy to treat COVID-19 patients who are 18 or above and are being treated in the intensive care unit (ICU) with confirmed or imminent respiratory failure. Industrial Info is tracking 19 projects from Biocon and its subsidiaries worth $224.57 million. Click here for a list and see map below.
(All Fields Required)
Site-wide Scheduled Maintenance for April 12, 2025, between 9 A.M. - 9 P.M. CST. During this time, all services will be unavailable periodically throughout the scheduled maintenance window.
×